Replies to post #999 on Bristol Myers Squibb (BMY)

[DewDiligence]

Nimbus Therapeutics (private) starts phase-2b of TYK2 inhibitor in psoriasis:

https://www.businesswire.com/news/home/20210914005150/en

This is potential competition for BMY’s Deucravacitinib.

[DewDiligence]

Deucravacitinib for psoriasis has 9/10/22 PDUFA date (with standard FDA review):

https://www.businesswire.com/news/home/20211129005192/en

The Deucra MAA in psoriasis has also been validated by the EMA.